Form 4: Cumberland Pharmaceuticals VP James L. Herman Reports Share Transactions
SEC Form 4
VP and Chief Compliance Officer of Cumberland Pharmaceuticals, James L. Herman, reports the disposition of shares to cover tax obligations and acquisition of options.
Summary
- James L. Herman, VP and Chief Compliance Officer of Cumberland Pharmaceuticals, filed a Form 4.
- On March 23, 2024, 1,186 shares of common stock were disposed of to cover tax withholding obligations at a price of $1.81 per share.
- Following the transaction, Herman directly owns 38,255 shares of common stock.
- On March 25, 2024, Herman acquired 4,000 options with an exercise price of $1.71, exercisable from March 25, 2028, and expiring on March 25, 2034.
- Following the transaction, Herman directly owns 16,000 options.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing share transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company executives.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/23/2024 | Disposition of 1,186 shares to cover tax obligations. |
| 03/25/2024 | Acquisition of 4,000 options. |
| 03/25/2028 | Options become exercisable. |
| 03/25/2034 | Options expire. |
| 03/26/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.